» Articles » PMID: 17142014

Validity of the EQ-5D in Assessing and Valuing Health Status in Patients with Schizophrenic, Schizotypal or Delusional Disorders

Overview
Journal Eur Psychiatry
Specialty Psychiatry
Date 2006 Dec 5
PMID 17142014
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The EQ-5D is a generic questionnaire generating a health profile and a single index score for health-related quality of life. This study aimed to analyse the discriminative ability and validity of the EQ-5D in patients with schizophrenic, schizotypal or delusional disorders.

Subjects And Methods: One hundred sixty-six patients with schizophrenic, schizotypal or delusional disorders (ICD-10 F2) completed the EQ-5D. Measures of quality of life (WHOQOL-BREF), utility (TTO), subjective (SCL-90R) and objective (PANSS, CGI-S) psychopathology, and functioning (GAF, GARF, SOFAS, HoNOS) provided comparison. Discriminative ability was analysed by assessing frequency distributions of EQ-5D scores. Validity of the EQ-5D self-classifier was analysed by assessing differences in related other scores grouped by response levels of EQ-5D items. Validity of the visual analogue scale (EQ VAS) and the EQ-5D index (UK social tariff) was analysed by assessing their correlation with all other scores.

Results: Seventy-nine percent of respondents reported problems in at least one of the EQ-5D dimensions (anxiety/depression 57%, usual activities 45%, pain/discomfort 44%, self-care 29%, mobility 22%). The mean EQ VAS score/EQ-5D index was 65.7/0.71. The four most frequently reported EQ-5D health states covered 45% of all respondents. For almost all EQ-5D dimensions, different response levels were associated with significantly different scores of measures used for comparison. Correlation of EQ VAS score and EQ-5D index were largest with scores of subjective measures (SCL-90R: -0.50 and -0.73; WHOQOL mental subscore 0.62 and 0.58; always P<0.001).

Discussion And Conclusion: The EQ-5D showed a moderate ceiling effect and seems to be reasonably valid in this patient group.

Citing Articles

Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia.

Boskovic D, Smith-Palmer J, Pohlmann J, Pollock R, Hwang S, Bruhn D Patient Relat Outcome Meas. 2024; 15:199-217.

PMID: 38911609 PMC: 11192194. DOI: 10.2147/PROM.S454845.


Value of gym-based group exercise versus usual care for young adults receiving antipsychotic medication: study protocol for the multicenter randomized controlled Vega trial.

Rafn B, Andersen M, Sorensen V, Bjerre E, Baandrup L, Vernal D BMC Psychiatry. 2023; 23(1):634.

PMID: 37648977 PMC: 10466717. DOI: 10.1186/s12888-023-05086-z.


Exploring Personal Recovery in Schizophrenia: The Role of Mentalization.

Concerto C, Rodolico A, Mineo L, Ciancio A, Marano L, Romano C J Clin Med. 2023; 12(12).

PMID: 37373783 PMC: 10299717. DOI: 10.3390/jcm12124090.


Exposure-based treatments for childhood abuse-related post-traumatic stress disorder in adults: a health-economic evaluation.

Kullberg M, Schoorl M, Oprel D, Hoeboer C, Smit F, van der Does W Eur J Psychotraumatol. 2023; 14(1):2171752.

PMID: 37052103 PMC: 9930771. DOI: 10.1080/20008066.2023.2171752.


Evaluating the implementation of a multidisciplinary lifestyle intervention for people with severe mental illness in sheltered housing: effectiveness-implementation hybrid randomised controlled trial.

Smit M, Waal E, Tenback D, Deenik J BJPsych Open. 2022; 8(6):e201.

PMID: 36412504 PMC: 9707511. DOI: 10.1192/bjo.2022.600.